猫肥厚性心肌病的先进治疗方法：动物模型和靶向治疗的作用。

Advancing Treatments for Feline Hypertrophic Cardiomyopathy: The Role of Animal Models and Targeted Therapeutics.

作者信息

Kaplan Joanna L, Rivas Victor N, Connolly David J

机构信息

Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA, USA.

出版信息

Vet Clin North Am Small Anim Pract. 2023 Nov;53(6):1293-1308. doi: 10.1016/j.cvsm.2023.05.011. Epub 2023 Jul 4.

DOI:10.1016/j.cvsm.2023.05.011

PMID:37414693

Abstract

Feline HCM is the most common cardiovascular disease in cats, leading to devastating outcomes, including congestive heart failure (CHF), arterial thromboembolism (ATE), and sudden death. Evidence demonstrating long-term survival benefit with currently available therapies is lacking. Therefore, it is imperative to explore intricate genetic and molecular pathways that drive HCM pathophysiology to inspire the development of novel therapeutics. Several clinical trials exploring new drug therapies are currently underway, including those investigating small molecule inhibitors and rapamycin. This article outlines the key work performed using cellular and animal models that has led to and continues to guide the development of new innovative therapeutic strategies.

摘要

猫肥厚型心肌病（Feline HCM）是猫最常见的心血管疾病，会导致包括充血性心力衰竭（CHF）、动脉血栓栓塞（ATE）和猝死等毁灭性后果。目前缺乏证据表明现有疗法能带来长期生存益处。因此，探索驱动肥厚型心肌病病理生理学的复杂基因和分子途径以推动新型疗法的开发势在必行。目前正在进行多项探索新药疗法的临床试验，包括研究小分子抑制剂和雷帕霉素的试验。本文概述了利用细胞和动物模型开展的关键工作，这些工作促成并持续指导着新的创新治疗策略的开发。